

WHEN AND WHY SHOULD I USE CHEMOTHERAPY TO TREAT PATIENTS WITH PROSTATE CANCER?

Friday 7 October 2016
18:00–20:00

Athens Auditorium—Bella Center
Copenhagen, Denmark

Please join us at 17:30 for a reception
preceding the start of the symposium



FACULTY

Karim Fizazi, MD, PhD (Chair)

*Institut Gustave Roussy
Villejuif, France*

Oliver Sartor, MD

*Tulane University School of Medicine
New Orleans, LA, USA*

Johann de Bono, MD, PhD

*The Institute of Cancer Research
The Royal Marsden NHS Foundation Trust
London, UK*

Scott Tagawa, MD

*Weill Cornell Medical College
Cornell University
New York, NY, USA*

AGENDA

18:00–18:10 Welcome and Introduction

Karim Fizazi, MD, PhD

18:10–18:30 Prostate Cancer as a Chemosensitive Disease

Karim Fizazi, MD, PhD

18:30–18:50 When and How to Use Chemotherapy for First-Line Metastatic Castrate Resistant Prostate Cancer (mCRPC) in 2016?

Oliver Sartor, MD

18:50–19:10 Why Use Chemotherapy for mCRPC in the Second-Line Setting?

Johann de Bono, MD, PhD

19:10–19:30 Differentiating Taxanes from Other mCRPC Therapies

Scott Tagawa, MD

19:30–19:50 Panel Discussion

All

19:50–20:00 Closing Remarks

Karim Fizazi, MD, PhD